BALTIMORE, Aug. 3 /PRNewswire/ -- BioFortis announced today that the pediatric, developmental and genetic opthamology laboratory at the National Eye Institute has adopted Labmatrix(TM), BioFortis' enterprise translational research data management application, to support family-based genetic studies. The laboratory, headed by Dr. Brian P. Brooks, MD, PhD, integrates both clinical and basic research focusing on uveal coloboma, a potentially blinding, developmental abnormality of the eye caused by failure of the optic fissure to close during the 5th week of human gestation. Labmatrix will be used to store, track and query clinical exam data with molecular genetic findings and maintain a well-documented biorepository. Labmatrix' HL7 interface will be used to maintain synchronization of clinical data between Labmatrix and the National Eye Institute Electronic Medical Record system.
"Labmatrix is an extraordinary tool to organize my science," says Dr. Brian Brooks, principal investigator of the study. "It allows me to seamlessly integrate what I am doing in the clinic with what I am doing at the bench." "The ability of Labmatrix to merge disparate datasets, especially clinical findings with family genetic and molecular analytical results, is a huge benefit for translational research studies such as those conducted at the National Eye Institute," explains Dr. Ethel Rubin, Ph.D., Chief Scientific Officer of BioFortis. "Labmatrix streamlines the information management needs of Dr. Brooks' lab. We are delighted that Labmatrix is being used to facilitate the scientific inquiry that will hopefully lead to new insights into this developmental disorder."
About BioFortis
BioFortis, located at the Emerging Technology Center in Baltimore, Maryland, is a privately-held company focused on providing biomedical research software and services to the life sciences sector, including clinical and basic research laboratories within academic medical centers, government labs, non-profit institutes, research consortia and the biopharmaceutical industry. BioFortis' flagship product Labmatrix(TM) enables transparent data management, integration, collaboration and compliance to privacy regulations. Labmatrix encompasses data management and cross-cutting query capabilities across patient information, biological sample data, workflow and storage, disease phenotypes, genotypes, clinical and molecular data, study and IRB protocol management.
BioFortis, Inc.CONTACT: Jian Wang, Ph.D., President & CEO of BioFortis, Inc.,+1-410-327-4082 x 1167, info@biofortis.com
Web site: http://www.biofortis.com//
